This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fisher, C.J. Search for Related Content PubMed Articles by Fisher, C.J., JR Social Bookmarking                         What's this?

Can second-generation versions of existing therapeutics be successful in clinical trials of sepsis?

Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA

Sepsis syndrome and septic shock remain as significant causes of morbidity and mortality. To date, clinical trials of immunotherapeutic agents have failed to establish conclusively a role for these agents despite considerable animal data to suggest a positive benefit. This article discusses the hypotheses upon which these therapies are based, the critical issues associated with clinical trials and the molecules which have been clinically tested. Recommendations for future clinical trials in sepsis are made.

Journal of Endotoxin Research, Vol. 2, No. 3, 227-232 (1995)
DOI: 10.1177/096805199500200314


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?